QDEL завтра будет новый quidel Quidel and Ortho Announce Expected Closing of Ortho Transaction SAN DIEGO—(BUSINESS WIRE)— Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England and Wales issued an order under Part 26 of the UK Companies Act sanctioning the scheme of arrangement to be undertaken by Ortho in connection with the business combinations (the “Ortho Scheme Order”). The order will become effective once the Ortho Scheme Order is duly filed with the Registrar of Companies in England and Wales, which is expected to occur on May 27, 2022, at which point Ortho will become a wholly owned subsidiary of Coronado Topco, Inc. (“Topco”). Following the effectiveness of a merger involving Quidel that will take place after the effectiveness of the Ortho Scheme Order, Quidel will also become a wholly owned subsidiary of Topco, and Topco will be renamed QuidelOrtho Corporation. Shares of common stock of QuidelOrtho are expected to begin trading on the Nasdaq Global Select Market at the open of business on May 27, 2022 under the symbol “QDEL.” Shares of Quidel and Ortho will cease trading after the market close on May 26, 2022, and following the closing, Ortho will no longer be listed on Nasdaq. QuidelOrtho will be the successor to Quidel for purposes of the combined company’s Nasdaq listing.

QDEL SAN DIEGO—(BUSINESS WIRE)— Quidel Corporation (NASDAQ: QDEL) (“Quidel”),a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million. COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue® COVID-19 test revenue and approximately $138 million in Sofia® SARS antigen test revenue. “We had another outstanding quarter and an excellent start to the year, delivering a record quarter for revenue,” said Douglas Bryant, President and Chief Executive Officer of Quidel. “In the first quarter of 2022, we sold approximately 113 million QuickVue COVID-19 antigen tests and approximately 12 million Sofia SARS antigen tests. We also expanded our installed base of Sofia analyzers to 79,000 instrument placements, which further widens our point-of-care footprint and increases opportunities to introduce our full portfolio of assays to patients and healthcare providers.” Mr. Bryant concluded, “Thanks to the continued dedication of our people, Quidel is well-positioned to deliver strong performance for the year and advance our mission to expand access to accurate, affordable diagnostic testing in professional, retail and government sectors.” These preliminary results are based on management’s initial analysis of operations for the quarter ended March 31, 2022. Quidel expects to issue full financial results for the first quarter of 2022 in May.

QDEL Quidel сегодня получил EUA одобрение FDA для QuickVue быстрых тестов на COVID. Отличие этого одобрение от прошлого, полученного в марте, в том, что теперь не нужен рецепт от доктора/врача. Quidel недавно начал строить новый завод, который будет принят в эксплуатацию во второй половине 2021 с изначальной целью производить 50 млн QuickVue COVID тестов в месяц. P.S. Ждем информацию по цене за такой тест, чтобы понимать максимальный объем продаж в долларах